Anthony Reder, MD
Neurology · Burr Ridge, ILNPI 1467503441
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $199,094 of the $266,045 with a category attached, or 74.8%. It is spread thinly across 24 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2019 at $97,611 and has fallen 76.1% since, to $23,342 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $1099.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$51K
- Merck Kgaa$43K
- Genentech, Inc.$42K
- EMD Serono, Inc.$40K
- Biogen$15K
- Novartis$13K
- plus $62K from 18 others
Across 177 payments — averaging $7663.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$458K
- AbbVie$372K
- E.r. Squibb & Sons, L.L.C.$358K
- Roche Products Limited$72K
- Biogen$58K
- F. Hoffmann-la Roche AG$22K
- plus $16K from 3 others
What the payments were for
- Consulting fees$199,09475%
- Speaking & faculty fees$41,84616%
- Travel & lodging$14,2175%
- Food & beverage$10,4324%
- Education$4560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 45 | $51,163 |
| Merck Kgaa | 4 | $42,850 |
| Genentech, Inc. | 31 | $42,174 |
| EMD Serono, Inc. | 59 | $39,521 |
| Biogen | 22 | $15,105 |
| Novartis | 11 | $12,733 |
| Viatris Specialty LLC | 1 | $10,660 |
| Bristol Myers Squibb | 13 | $7,820 |
| Sanofi | 13 | $7,569 |
| Mylan Institutional Inc. | 11 | $6,567 |
| Mylan Specialty L.p. | 3 | $5,312 |
| Bayer | 1 | $4,000 |
| Amgen | 4 | $3,799 |
| AbbVie | 2 | $3,575 |
| TG Therapeutics, Inc. | 2 | $3,440 |
| Johnson & Johnson | 1 | $3,000 |
| Janssen Scientific Affairs, LLC | 1 | $1,620 |
| F. Hoffmann-la Roche AG | 2 | $1,493 |
| Cycle Pharmaceuticals Inc | 1 | $1,300 |
| Banner Life Sciences, LLC | 1 | $900 |
| AstraZeneca | 7 | $725 |
| E.r. Squibb & Sons, L.L.C. | 4 | $480 |
| Eisai Inc. | 2 | $178 |
| Mallinckrodt Enterprises LLC | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$266,045 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $432,933 |
| Plegridy PenPeginterferon Beta-1a | 40 | $371,217 |
| Kesimpta PenOfatumumab | 29 | $264,694 |
| BetaseronInterferon Beta-1b | 24 | $251,437 |
| CopaxoneGlatiramer Acetate | 45 | $225,406 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $157,503 |
| RebifInterferon Beta-1a/Albumin | 15 | $145,501 |
| VumerityDiroximel Fumarate | 19 | $120,891 |
| AubagioTeriflunomide | 12 | $109,018 |
| PlegridyPeginterferon Beta-1a | 13 | $107,456 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $107,450 |
| GlatopaGlatiramer Acetate | 13 | $38,236 |
| Dalfampridine ErDalfampridine | 34 | $17,457 |
| Emgality PenGalcanezumab-Gnlm | 16 | $14,443 |
| Gabapentin | 87 | $2,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerBetaseron | $4,000 | $251,43724 claims |
| BiogenVumerity, Plegridy | $15,105 | $228,34732 claims |
| EMD Serono, Inc.Rebif | $39,521 | $145,50115 claims |
| SanofiAubagio | $7,569 | $109,01812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Burr Ridge
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.